ArticleESC heart failure2023

SGLT2 inhibitor therapy for transthyretin amyloid cardiomyopathy: early tolerance and clinical response to dapagliflozin.

Stephan Dobner et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.